bioAffinity Technologies Inc.
bioAffinity Technologies Inc. (BIAF): 2 pipeline candidates · ~3 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.2 months
D/E 1.17 · 0% dilution
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for bioAffinity Technologies Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.9M
Cash
$3.1M
Quarterly Burn
$3.2M
Runway
3.2 mo
Revenue
$1.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| companion diagnostic tests for asthma | Preclinical |
| cypath lung | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
9
Total value held
$927K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 111,086 | $425K |
| geode capital management, llc | 48,293 | $185K |
| vanguard fiduciary trust co | 31,071 | $119K |
| schonfeld strategic advisors llc | 24,413 | $94K |
| state street corp | 14,386 | $55K |
| northern trust corp | 12,725 | $49K |
| citigroup inc | 57 | $218 |
| morgan stanley | 3 | $11 |
| caitong international asset management co., ltd | 1 | $4 |
Frequently asked questions
How many drug candidates are in bioAffinity Technologies Inc.'s pipeline?
bioAffinity Technologies Inc. (BIAF) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is bioAffinity Technologies Inc.'s lead drug candidate?
bioAffinity Technologies Inc.'s most advanced tracked candidate is companion diagnostic tests for asthma (Preclinical) for Asthma and chronic obstructive pulmonary disease (COPD).
What is bioAffinity Technologies Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, bioAffinity Technologies Inc. has approximately 3.2 months of cash runway.
What is bioAffinity Technologies Inc.'s market capitalization?
bioAffinity Technologies Inc.'s market capitalization is approximately $4.9M.
Who is the CEO of bioAffinity Technologies Inc.?
Ms. Maria Zannes J.D. is the chief executive officer of bioAffinity Technologies Inc. (BIAF).
Get the full picture on bioAffinity Technologies Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.